Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Pimodivir and Pimodivir/Oseltamivir FDC in Healthy Adults
NCT03023852Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2017
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pimodivir in Influenza A (IAV) (8 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration at Day 5, Time to Reach Maximum Observed Plasma Concentration at Day 5 and 4 more. Started Feb 2017; status: completed.
02
Drugs
pimodivir
03
Conditions
Influenza A (IAV)
Beyond the preview
Go deeper on NCT03023852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03023852.